GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today
reported that new pre-clinical data on RGB-286638, the Company’s
multi-targeted protein kinase inhibitor, were presented at the 50th
American Society of Hematology (ASH) Annual Meeting in San Francisco,
California in a poster entitled, “RGB-286638, a Novel Multi-Targeted
Small Molecule Inhibitor, Induces Multiple Myeloma (MM) Cell Death
through Abrogation of CDK-Dependent and Independent Survival Mechanisms”
(Poster Board II-853). The data presented demonstrate that, in a mouse
tumor model, RGB-286638 inhibits the growth of multiple myeloma tumors
and prolongs survival. Additionally, RGB-286638 has been shown to
trigger apoptosis (programmed cell death) in multiple myeloma cells,
including those cells that are resistant to drugs commonly used to treat
this form of cancer. The data were presented by researchers at the
Dana-Farber Cancer Institute and the Massachusetts General Hospital
Cancer Center (MGH), Boston, Massachusetts.
“The data presented today suggest the potential role of RGB-286638 in
the treatment of multiple myeloma,” said Martine George, M.D., Senior
Vice President, Drug Development and Chief Medical Officer of GPC
Biotech. “We are working with the MGH/Dana-Farber team to plan a Phase 1
study in hematological tumors, including multiple myeloma, which we
expect to start in 2009. The first-in-humans study with this compound, a
Phase 1 trial evaluating RGB-286638 in solid tumors, is expected to
start in the near future.”
About RGB-286638
RGB-286638 is a multi-targeted protein kinase inhibitor entering Phase 1
clinical testing. The RGB-286638 compound has been shown in cancer cells
to lead to the inhibition of cell cycle progression, the process that
controls cell division and ensures the accurate duplication of genetic
material, by targeting all relevant cyclin-dependent kinases, which are
proteins involved in regulating the cell cycle. RGB-286638 has also been
shown to induce apoptosis and to inhibit other major protein kinases
that are important for the proliferation of cancer cells. In a range of
pre-clinical models of solid and hematological tumors, RGB-286638
treatment results in tumor regression and increased survival.
About GPC Biotech
GPC Biotech AG is a publicly traded biopharmaceutical company focused on
anticancer drugs. GPC Biotech's lead product candidate is satraplatin,
an oral platinum compound. The Company has various anti-cancer programs
in research and development that leverage its expertise in kinase
inhibitors.
